- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 Inhibitor (DPP-4), Glucagon-Like Peptide-1 Agonist (GLP-1), Thiazolidinedione (TZD), Sulfonylureas, Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25,358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Trevose, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 41
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
- Interventions
- Sitagliptin, glargine, lispro
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Type II Diabetes
- Interventions
- Sitagliptin, Placebo
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 14
- States / cities
- Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- PHX1149T, Placebo
- Drug
- Lead sponsor
- Phenomix
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 13
- States / cities
- Norwalk, California • Orange, California • Santa Ana, California + 10 more
- Conditions
- Disorder of Glucose Regulation
- Interventions
- Sitagliptin-Metformin, Metformin, Placebo pill
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Diabetes
- Interventions
- Empagliflozin, DPP-4 inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 103,752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes, Cardiac Disease
- Interventions
- Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 386,301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lewy Body Dementia, Parkinson Disease
- Interventions
- Sitagliptin, Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 45 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- linagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166,613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes
- Interventions
- linagliptin, insulin glargine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Decatur, Georgia
- Conditions
- Diabetes
- Interventions
- Canagliflozin, DPP-4 inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152,202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes
- Interventions
- Liraglutide, DPP-4 inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 50 Years to 120 Years
- Enrollment
- 168,690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus, Type 2 Diabetes
- Interventions
- dutogliptin
- Drug
- Lead sponsor
- Phenomix
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 13
- States / cities
- Norwalk, California • Orange, California • Santa Ana, California + 10 more
- Conditions
- Diabetes Mellitus
- Interventions
- Saxagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sotagliflozin, Empagliflozin, Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Sheffield, Alabama • Hawaiian Gardens, California + 40 more
- Conditions
- Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
- Interventions
- Metformin, Sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, GLP1 receptor agonist
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,888 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Nashville, Tennessee
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- dutogliptin
- Drug
- Lead sponsor
- Phenomix
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 27
- States / cities
- Fullerton, California • Long Beach, California • Orange, California + 24 more
- Conditions
- Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
- Interventions
- Sitagliptin
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Type II Diabetes, Nonalcoholic Fatty Liver
- Interventions
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- dutogliptin, placebo
- Drug
- Lead sponsor
- Phenomix
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 34
- States / cities
- Montgomery, Alabama • Tempe, Arizona • Anaheim, California + 27 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Empagliflozin, DPP-4 inhibitor, GLP-1 receptor agonist
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts